Ingersoll Rand (IR) Q1 2026 earnings review
M&A Masks Organic Weakness and Margin Squeeze
Ingersoll Rand delivered an 8% revenue increase and 7% Adjusted EPS growth, but the headline numbers hide underlying operational stress. Organic revenue actually declined 0.3%, with the top line entirely propped up by M&A and FX tailwinds. The biggest concern is the core Industrial Technologies & Services (IT&S) segment, where operating margins collapsed by 210 basis points due to volume deleverage and tariff impacts. While the smaller P&ST segment executed brilliantly, total free cash flow fell 27%. The company maintained its FY26 guidance, but achieving it will require a significant second-half organic rebound.
🐂 Bull Case
Acquisitions added nearly 4% to top-line growth. With $3.9B in liquidity and deals like Scinomix and Fox s.r.l. recently secured, inorganic growth will comfortably support FY26 targets.
The Precision & Science Technologies segment expanded margins by 120 bps to 30.3% while delivering 4% organic growth, proving the IRX operating model works when volume cooperates.
🐻 Bear Case
IT&S generates ~80% of total revenue, and its margin fell from 28.8% to 26.7%. If tariff pricing and volume declines persist, total company profitability will stall.
Free cash flow plummeted 27% to $163M as inventory built up and accounts payable shrank, threatening the company's 95% cash conversion target.
⚖️ Verdict: ⚪
Neutral. Management is executing well on the things they can control (M&A, buybacks, P&ST margins), but the organic volume declines and severe margin squeeze in their largest segment cannot be ignored.
Key Themes
IT&S Margin Contraction Contradicts 'Momentum'
Decelerating. CEO Vicente Reynal cited 'solid momentum' to start the year, but a major red flag emerged in the core IT&S segment. Adjusted EBITDA margin plummeted from 28.8% a year ago to 26.7%. This sharp compression contradicts the positive narrative, driven by negative flow-through from organic volume drops and tariff pricing that merely offsets costs one-for-one without adding profit margin.
M&A Flywheel and Product Expansion
Stable. Acquisitions remain the primary growth driver, generating 3.7% of the quarter's 8% revenue growth. The company deployed $52M to acquire Scinomix (adding automation workflow technologies for life sciences) and announced the acquisition of Fox s.r.l. to enhance its dosing pump portfolio with hydropneumatic accumulators.
P&ST Profitability Engine
Accelerating. The Precision & Science Technologies (P&ST) segment was the standout operational performer. Margins expanded 120 basis points YoY to 30.3%, fueled by a 4% increase in organic revenue. Strong implementation of the Ingersoll Rand Execution Excellence (IRX) framework allowed this segment to completely avoid the company-wide margin pressure.
Organic Demand Stalls Amid Macro Headwinds
Reversing. While reported revenue looks healthy, organic revenue reversed course, dropping 0.3%. IT&S organic orders were even weaker, down 3%. Management explicitly blamed the Middle East macro conflict for the order drag; however, even excluding that region, IT&S orders were entirely flat, indicating a lack of underlying core volume growth.
Tariff Mitigation Strategy
Stable. The company successfully executed pricing actions to offset Section 232 tariff costs on a one-for-one dollar basis. While this mathematically dilutes the overall EBITDA margin percentage (as clearly seen in the IT&S segment), it successfully protects absolute operating profit dollars in a highly inflationary supply chain environment.
Working Capital Pressures Free Cash Flow
Reversing. Free cash flow dropped 27% YoY to $163M. Operating cash flow was significantly weighed down by a $74.7M inventory build and a massive $133.5M reduction in accounts payable. Management must quickly reverse this working capital drain to hit their ~95% FCF conversion guidance for the year.
Other KPIs
Reversing. Cash generation dropped 27% YoY from $222.7M in 25Q1, dropping the FCF margin from 13.0% to 8.8%. The decline was driven entirely by adverse working capital movements, specifically inventory accumulation.
Stable. A slight uptick from 1.6x a year ago, reflecting ongoing capital deployment including $52M for acquisitions and $89M in share repurchases. Total liquidity remains exceptionally strong at $3.9 billion.
Guidance
Decelerating vs current quarter. Maintained guidance implies a slowdown from the 8% reported in 26Q1. Crucially, it relies heavily on non-organic factors (M&A +2%, FX +0.5%), with organic growth projected at just flat to 2%.
Stable. Represents an implied ~4% YoY growth at the midpoint. Phasing is expected to be 46% in 1H and 54% in 2H, meaning margin improvement is heavily back-end loaded and requires significant execution given the Q1 IT&S margin collapse.
Stable. The midpoint of $3.51 implies a 5% YoY increase. This looks highly achievable given the ongoing share repurchases (lowering the denominator) and positive contribution from recent acquisitions.
Key Questions
IT&S Margin Recovery Path
With IT&S margins down 210 basis points in Q1 due to tariffs and volume deleverage, what are the specific operational levers within the IRX system that will drive the guided second-half margin expansion?
Middle East Order Deferrals
You noted the Middle East conflict impacted IT&S orders and expect to recover them later this year. Given the ongoing geopolitical volatility, what gives you confidence these are merely deferred rather than lost entirely?
Inventory Build Dynamics
Inventory consumed $75 million in cash this quarter. Is this an intentional build to mitigate supply chain and tariff risks, or a symptom of the organic volume declines?
Pricing Power Limits
With organic volume already slightly negative, how much capacity remains to raise prices further to offset ongoing tariff costs before it begins to destroy end-market demand?